Weizmann Institute of Science participated in a series B round for its spinout that was originally known as OnSight Medical.
UltraSight, an Israel-based cardiac imaging technology developer spun out of Weizmann Institute of Science, completed a $13m series B round on Tuesday featuring the university.
Insurance provider Atain Specialty Insurance and venture capital fund Yozma Group Korea also took part in the round.
Originally known as OnSight Medical (at one point spelled On-Sight Medical), the company has built an artificial intelligence platform to conduct and analyse point-of-care ultrasound scans by doctors who have no prior sonography training.
Current approaches to cardiac ultrasound scans require years of training and daily practice to maintain proficiency. The technology is based on research at Weizmann, with additional work conducted at New York University.
UltraSight will use the money to advance US trials in a variety of clinical settings.
In conjunction with the round, UltraSight has appointed additional members to its medical and scientific advisory board: Al Lojewski, former general manager cardiology solutions at GE Healthcare, Dr Laurance Grossman, radiologist at Cleveland Clinic, and Andrew Cleeland, CEO of Fogarty Innovation.
UltraSight previously collected $2m from Yozma in 2019.
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
